AbbVie turns its back on Harpoon’s BCMA-targeting multiple myeloma drug

Ab­b­Vie is walk­ing away from an ex­clu­sive op­tion for Har­poon’s BC­MA-tar­get­ing T cell en­gager for mul­ti­ple myelo­ma, leav­ing the Cal­i­for­nia com­pa­ny to ad­vance the as­set alone.

The agree­ment will end on Oct. 12, af­ter which the drug, HPN217, will be ful­ly owned by Har­poon. The biotech said it would com­plete an on­go­ing Phase I tri­al of the as­set in re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma with in­ter­im da­ta to be pre­sent­ed at the an­nu­al In­ter­na­tion­al Myelo­ma So­ci­ety meet­ing on Sept. 28, with an eye to sup­port­ing fur­ther de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.